Reference

Validation of a chiral HPLC assay for (R)-salbutamol sulfate

Validation of a chiral HPLC assay for (R)-salbutamol sulfate. Halabi, Alejandra; Ferrayoli, Carlos; Palacio, Marcela; Dabbene, Viviana; Palacios, Sara (Unidad CEPROCOR, Agencia Cordoba Ciencia, Cordoba 5000, Argent.). Journal of Pharmaceutical and Biomedical Analysis, 34(1), 45-51 (English) 2004 Elsevier Science B.V. CODEN: JPBADA. ISSN: 0731-7085. DOCUMENT TYPE: Journal CA Section: 64 (Pharmaceutical Analysis) A fast, reliable, and specific method for the screening, confirmation, detn., and quantitation of salbutamol enantiomers was developed and validated. The described procedure includes a single robust chiral HPLC detn. employing a Teicoplanin stationary phase. The method was evaluated for specificity, robustness, linearity, precision, and accuracy. Under the chromatog. conditions of the method, known impurities were sepd. from the active principle.

Teicoplanin measurement in patients with renal failure: comparison of fluorescence polarization immunoassay: microbiological assay, and high-performance liquid chromatographic assay

Teicoplanin measurement in patients with renal failure: comparison of fluorescence polarization immunoassay: microbiological assay, and high-performance liquid chromatographic assay. Awni, W. M.; St. Peter, W. L.; Guay, D. R. P.; Kenny, M. T.; Matzke, G. R. (Div. Nephrol., Hennepin Cent. Med. Cent., Minneapolis, MN 55415, USA). Ther. Drug Monit., 13(6), 511-17 (English) 1991. CODEN: TDMODV. ISSN: 0163-4356. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Characterization of antibiotic pharmacokinetics in patients with renal insufficiency may be complicated by substances interfering within the assay. The authors compared three different assays for teicoplanin in serum and dialyzate of 10 hemodialysis and six continuous ambulatory peritoneal dialysis (CAPD) patients. The microbiol. assay (micro) had a within-run and between-run coeff. of variation (%CV) of <7.5% for concns. ranging from 0.2 to 96 mg/mL. The high-performance liq. chromatog. assay (HPLC) within- and between-run %CV was <8% for concns. ranging from 1 to 80 mg/mL. The fluorescence polarization immunoassay (FPIA) within- and between-run %CV was <7% for concns. ranging from 5 to 100 mg/mL. In serum of hemodialysis patients FPIA results were slightly higher than HPLC results: FPIA = 1.11 HPLC + 2.37 (r = 0.975, n = 202), and FPIA concns. in serum were also slightly higher than those measured by micro (FPIA = 1.21 micro - 1.57, r = 0.972, n = 161). The HPLC and micro serum results were also comparable in hemodialysis patients: micro = 0.92 HPLC + 2.89, r = 0.953, n = 160. However, in CAPD patients micro results were lower than HPLC results in serum (micro = 0.82 HPLC + 0.49, r = 0.981, n = 262). In peritoneal dialyzate, HPLC values were ~60% of the micro values. Thus, FPIA may be the optimal technique for therapeutic monitoring of teicoplanin in the clin. setting due to its simplicity, specificity, and good correlation to HPLC and micro.